Rod Raynovich's  Instablog

Rod Raynovich
Send Message
Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 30 years executive experience including Abbott and JNJ and has been involved three successful start-ups. He has a B.S, from Penn State University and an MBA from... More
My company:
Raygent Capital
My blog:
  • Confirm The Trading Bottom In Biotech With ETFs..Update At Close 0 comments
    Apr 15, 2014 2:31 PM | about stocks: IBB, XBI

    Update at Close 4/15….. Late Day Reversal To Green

    The NASDAQ Composite began a rally at 1P EDT and never stopped , moving up 62 points to close at 4034. Biotech ETFs followed step by step to end up in the green after a severe daily decline. The IBB ($217.6) ended up 1% after hitting allow near $207.68 at 1 Pm EDT.

    The XBI hit a low of $115 before rallying at 1P EDT to a $122.7 close . $115 is the Aug, Oct and Nov 2013 triple bottom.

    There should be a follow-up rally tomorrow in NASDAQ and large cap biotech stocks.


    Biotech Selling Is Relentless- But Off Daily Bottom

    NASDAQ Down 22.82 or 0.57% %, 4.25% YTD at 2:13P EDT; DOW and S&P flat but green

    See chart below on major biotech ETFs. FBT flat YTD, PBE up 2% YTD, IBB down 6% YTD

    and XBI down 8.17% YTD and now at October lows , a triple bottom near $115. The XBI SPDR S&P Biotech ETF has a $1.27B market cap was originally characterized as "equal weighted" and is small cap growth. There is frequent rebalancing of holdings for example with GERN, KERX, EXAS,ITMN and ACOR now among the top ten. At one time the XBI held many of the highly speculative and MOMO stocks like ARIA, GEVA, ICPT, INCY, NVAX, ONVO, SGMO, SRPTetc. We suspect that the model of XBI ($119) is MACD or MO based and whatever the case should be an indicator of small cap biotech bottom.The chart is currently in bear territory below the 200 day moving average. The 2014 high was 170 in late February.

    We recommendedXBI as a short to hedge a life science portfolio in February but it is too late to short now. We recommended a cash position in a life science portfolio at 30%.

    Other ETFs like FBT and IBB are more weighted to large caps.

    (click to enlarge)

    Disclosure: I am long GILD.

    Additional disclosure: I am long FBIOX Fidelity Select Biotech and short mid and small caps on a daily basis.

    Stocks: IBB, XBI
Back To Rod Raynovich's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.